AI assistant
BELLUSCURA PLC Share Issue/Capital Change 2021
7514_sha_2021-11-29_9c44876f-800c-461a-ba81-1cc6acf3611a.html
Share Issue/Capital Change
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 8019T
Belluscura PLC
29 November 2021
Belluscura PLC
("Belluscura" or "Company")
Exercise of Warrants and Total Voting Rights
LONDON, U.K. AND PLANO, TX, U.S. (29 November 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has received notification from a warrant holder to exercise warrants over 179,537 shares in the share capital of Belluscura ("the Warrant Shares") at exercise prices of 13 pence (139,537 shares) and 15 pence (40,000 shares). The consideration for the exercise of the Warrant Shares amounts, in aggregate, to a cash value of £24,139.81.
The Warrant Shares were allotted on 26 November 2021. Application has been made for the Warrant Shares to be admitted to trading on AIM ("Admission"), and Admission is expected to be on or around 2 December 2021. These shares will rank pari passu with the ordinary shares of the Company in issue.
Total voting rights
The Company's total issued capital, after the issue of the Warrant Shares, will be 113,486,938 ordinary shares. As the Company does not hold any shares in Treasury, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company following Admission.
| Belluscura plc | www.belluscura.com |
| Robert Rauker, Chief Executive Officer | via Walbrook PR |
| Anthony Dyer, Chief Financial Officer | |
| SPARK Advisory Partners Ltd (NOMAD) | Tel: +44 (0)20 3368 3550 |
| Neil Baldwin | |
| Dowgate Capital Ltd (Broker & Bookrunner) | Tel: +44 (0)20 3903 7715 |
| James Serjeant / Nicholas Chambers | |
| Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or [email protected] |
| Paul McManus / Sam Allen | Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
IOEEAEFPAFDFFAA